Technologies

1. Technical overview

This is a diagnostic index technique, which can be used for the detection of liver cancer with high precision, high convenience and simple non-invasive method.

two。 The effect of technology

The existing AFP labeling plus fibronectin (FINC) for the diagnosis of liver cancer using ELISA (enzyme-linked immunosorbent assay) kit

The diagnostic accuracy of level 1 was 94% in the blind test of 502 samples and 99% in the demonstration of 200 samples.

High precision and sensitivity, can predict and identify the early diagnosis, surveillance and disease transmission of liver cancer.

The use of non-invasive detection methods in blood or urine can be used to diagnose and monitor liver cancer easily and effectively.

Development of real-time test (POCT) for early detection of liver cancer in families and general clinics

It can be used to confirm the progress of treatment after the treatment of hepatocellular carcinoma.

3. Technical content

Biomarker detection reagents such as BASP1,PABPC1,CAPN1,ANLN,C4A,MTHFD1,ACADVL and FLNB were used to prepare biomarker detection reagents for the diagnosis of liver cancer.

The kit is a kit for the diagnosis or prognosis of hepatocellular carcinoma. It can be used for ELISA analysis, dipping rapid kit analysis, MRM analysis, microarray, gene amplification and immunoassay.

Methods for detection of markers in hepatocellular carcinoma,

-Detection of the presence of nucleic acids or proteins in ASP1,PABPC1,CAPN1,ANLN,C4A,MTHFD1,ACADVL and FLNB

-the detection results of the presence of nucleic acid or protein were compared with the corresponding marker results of the control sample.

-if, after comparison with the control sample, if the nucleic acid or protein level of the sample changes or if there is or does not exist a change in nucleic acid or protein, it is detected as hepatocellular carcinoma.